Genetic engineering approaches to improve post-translational modification of biopharmaceuticals in different production platforms

Thomas Amann, Valerie Schmieder, Helene Faustrup Kildegaard, Nicole Borth, Mikael Rørdam Andersen*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

71 Downloads (Pure)

Abstract

The number of approved biopharmaceuticals, where product quality attributes remain of major importance, is increasing steadily. Within the available variety of expression hosts, the production of biopharmaceuticals faces diverse limitations with respect to post-translational modifications (PTM), while different biopharmaceuticals demand different forms and specifications of PTMs for proper functionality. With the growing toolbox of genetic engineering technologies, it is now possible to address general as well as host- or biopharmaceutical-specific product quality obstacles. In this review we present diverse expression systems derived from mammalians, bacteria, yeast, plants, and insects as well as available genetic engineering tools. We focus on genes for knockout / knockdown and overexpression for meaningful approaches to improve biopharmaceutical PTMs and discuss their applicability as well as future trends in the field. This article is protected by copyright. All rights reserved.
Original languageEnglish
JournalBiotechnology and Bioengineering
Volume116
Issue number10
Pages (from-to)2778-2796
ISSN0006-3592
DOIs
Publication statusPublished - 2019

Keywords

  • CRISPR
  • Cell Engineering
  • Chinese Hamster Ovary
  • Expression System
  • Post-translational Modification

Fingerprint Dive into the research topics of 'Genetic engineering approaches to improve post-translational modification of biopharmaceuticals in different production platforms'. Together they form a unique fingerprint.

Cite this